PTGS2 and Alzheimer disease: More importantly, the effects of PGI2 might be responsible for the cause for the failure of clinical trials for COX-2-specific inhibitors because these trials did not take into consideration the suppressive effects of PGI2 on the neuroinflammation of AD.